CONNECT WITH US
HealthTech

HealthTech

AAO: Sequential nonarteritic anterior ischemic optic neuropathy occurs earlier with GLP-1 receptor agonist exposure

Medical Xpress logo

Published on

Add as a preferred source on Google
AAO: Sequential nonarteritic anterior ischemic optic neuropathy occurs earlier with GLP-1 receptor agonist exposure

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

For patients with nonarteritic anterior ischemic optic neuropathy (NAION), glucagon-like peptide-1 (GLP-1) receptor agonist exposure is associated with earlier sequential NAION, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held Oct. 9 to 12 in New Orleans.

Ashley Tin, from the Carle Illinois College of Medicine in Urbana, and colleagues examined whether GLP-1 receptor agonist exposure is associated with earlier sequential NAION. Early (one to six months) versus late (36 to 60 months) events were compared in 1,440 GLP-1 receptor agonist users and 20,713 nonusers, stratified by pre- and post-GLP-1 receptor agonist eras.

The researchers found that the early event concentration was higher for GLP-1 receptor agonist users, with 69.5% versus 52% of events occurring within six months in users and nonusers, respectively (relative risk, 2.63). Across eras, findings were consistent. Higher hemoglobin A1c was seen in GLP-1 receptor agonist users versus nonusers.

"We were not particularly surprised by the findings because the large-database analysis was consistent with the clinical observation that prompted the study," Tin said in a statement. "That said, seeing the clinical impression reproduced across a very large data set was striking and underscored the need to investigate the association further."



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.